<DOC>
	<DOCNO>NCT01041274</DOCNO>
	<brief_summary>This study seek examine effectiveness citalopram add treatment oral injectable second-generation antipsychotic plus standardized psychoeducation first episode schizophrenia patient . Because depressive symptom common first episode patient , test hypothesis add SSRI citalopram pre-established medication regimen improve quality life decrease relapse suicidality course 12-month trial .</brief_summary>
	<brief_title>DECIFER : Depression Citalopram In First Episode Recovery</brief_title>
	<detailed_description>We propose conduct 12-month , placebo-controlled , double-blind , parallel-group trial citalopram add treatment oral injectable second-generation antipsychotic plus standardized psychoeducation . Subjects 100 patient age 16-40 first episode schizophrenia schizophreniform disorder onset age 35 receive least 4 week few 16 cumulative week antipsychotic medication , treat SSRI within four week meet criterion major depression significant suicidal ideation . This study conduct Schizophrenia Program NYU Langone Medical Center Psychiatry Outpatient Clinic Bellevue Hospital locate New York , NY Upon sign consent , patient undergo screen procedure assess eligibility . A diagnosis schizophrenia schizophreniform disorder determine Structured Clinical Interview DSM IV ( SCID ) complete research clinician use available clinical data confirm consensus diagnosis . A comprehensive medical history physical exam , include measurement vital sign , perform . A psychiatric history , include diagnosis , treatment history , current medication , substance use also perform . At screening , fast blood sample obtain perform routine laboratory test include electrolyte , BUN , creatinine , liver function test , fast glucose , calcium , phosphate , magnesium , albumin CBC differential . Urinalysis perform identify unstable medical illness . A urine toxicology screen perform urine pregnancy test do woman child bear potential . A research assistant complete demographic administer Calgary Depression Scale Schizophrenia ( CDSS ) , Scale Assessment Negative Symptoms ( SANS ) InterSePT Scale Suicidal Thinking ( ISST ) determine whether inclusion criterion meet . Subjects meet study eligibility criterion complete baseline assessment include follow assessment : Brief Psychiatric Rating Scale ( BPRS ) , SANS , CDSS , ISST , Clinical Global Impression Severity Suicidality ( CGI-SS ) , Clinical Global Impression ( CGI ) , Heinrich Quality Life Scale ( QLS ) , WHO Quality Life Scale ( WHO-QOL ) , Scale Assessment Positive Symptoms-Delusions ( SAPS-D ) , Birchwood Insight Scale ( IS ) , Brief Time Use Survey ( BTUS ) , MIRECC Global Assessment Functioning ( MIRECC GAF ) , Beck Depression Inventory-II ( BDI-II ) , State-Trait Anxiety Inventory ( STAI ) , MacArthur Perceived Coercion Scale ( PCS ) , Basis-24 , Subject Well-being Neuroleptic Scale ( SWN-S ) , Subjective Scale Investigate Cognition Schizophrenia ( SSTICS ) , Brief Adherence Rating Scale ( BARS ) , Medication Adherence Rating Scale ( MARS ) , Social Behavior Scale ( SBS ) , WHO Alcohol Smoking Substance Involvement Screening Test ( WHO ASSIST ) , Drug Use Survey . In addition , side effect rat use Systematic Assessment Treatment Emergent Events ( SAFTEE ) , Abnormal Involuntary Movement Scale ( AIMS ) , Barnes Akathisia Scale ( BAS ) Simpson Angus Scale Extrapyramidal Symptoms ( SAS ) . Assessment cognitive functioning measure MATRICS battery . Subjects undergo 4 high-resolution MP-RAGE scan : Baseline , 2 month , 6 month 12 month . Scheduled Participants randomize 1:1 citalopram placebo . We follow standard approach flexible dose citalopram recommend manufacturer , initiate treatment dose 20 mg ( two capsule ) daily . Clinicians may increase decrease dose one capsule every two week maximum 4 capsule minimum one capsule daily . Beginning Week 1 , participant receive 16 session weekly , individual psychoeducation relapse prevention planning follow 8 monthly session . Participants score 3 ( moderate suicidality ) CGI-SS &gt; 7 CDSS treat standard 12 session CBT approach depression include element target suicidality appropriate . Clinical judgment use determine whether offer CBT depression session twice weekly . The CDSS , ISST , CGI-SS administer baseline weekly week 8 , monthly . The SANS , BPRS , BARS administer baseline , monthly duration study . The Heinrich 's QOL WHO QOL administer baseline , monthly study completion , except week 28 , week 36 , week 44 , week 48 . The SAPS-D , IS , BTUS , MIRECC GAF , CGI , STAI , PCS , Basis-24 , SWN-S , SSTICS , MARS , SBS administer baseline , week 24 , week 52 . The BDI-II administer screening , baseline , week 1-16 , monthly . The WHO-ASSIST administered baseline , week 12 , week 24 , week 52 . The drug use survey administer baseline , week 4 , week 8 , week 12 , week 16 , week 20 , week 24 , week 52 . A fasting blood sample drawn Baseline , week 4 8 every 8 week thereafter BDNF assay . Blood sample collect Baseline , week 24 , week 52 assay prolactin inflammation marker . Blood sample collect baseline , week 8 , week 24 , week 52 assay C-Reactive Protein . Additionally , blood sample DNA collect week 4 . Saliva collect tongue swab Baseline , Week 4 , Week 8 , Week 16 , Week 24 , Week 36 , Week 52 cortisol analysis . Participants choose discontinue study drug ask willing continue schedule assessment . These subject continue follow entire course study receive study medication . Final study visit conduct 1 year post randomization . The primary outcome measure change depression symptom measure Calgary Depression Scale total score . Secondary outcome measure include measure change negative symptom ( SANS ) , relapse rate ( BPRS ) , suicidal ideation ( ISST ) , quality life ( QOL ) , measure various time point 12-month trial .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Male female Ages 1640 year Schizophrenia , subtype Schizophreniform disorder Treated follow second generation antipsychotic least 4 week few 16 week : risperidone , olanzapine , quetiapine , aripiprazole , ziprasidone , paliperidone ) Willing participate psychoeducation Sufficient proficiency English complete assessment Major depression DSMIV criterion Clinical Global Assessment Severity Suicidality 3 ( moderate ) great . Calgary Depression Scale Schizophrenia ( CDRS ) score 7 great Serious suicide attempt within three year ANY suicide attempt subject age 1625 . Current treatment MAOI pimozide Active alcohol substance abuse dependence within three month Unstable medical illness History SSRI intolerance Pregnant nursing QTc â‰¥ 500 msec</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Citalopram</keyword>
	<keyword>First episode</keyword>
	<keyword>fMRI</keyword>
	<keyword>Cognitive behavioral therapy</keyword>
	<keyword>Psychoeducation</keyword>
</DOC>